UNSPSC 51432312: Imidapril monohydrochloride

This classification denotes an ace inhibitor with the molecular formula C20H27N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7NSF9GG1NU, chemically known as 3-((2s)-2-((1s)-n-(1-ethoxycarbonyl-3-phenylpropyl)amino)-propionyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid, hydrochloride-, 4s-, but more generally known as imidapril monohydrochloride, which bears US NIH Compound Identifier 5485193.

European Medicines Agency schedules imidapril monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08143MIG. Most nations, for tariff purposes, schedule imidapril monohydrochloride under HS 29332990. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O.CL.

UNSPSC 51432312 Imidapril monohydrochloride is a Commodity code covering pharmaceutical active pharmaceutical ingredients and finished medications used in emergency medicine and state health programs. State and local governments procure under this code primarily through emergency medical services departments (fire rescue services) and state health and human services agencies seeking advanced life support medications and generic multi-source pharmaceuticals for distribution across government healthcare facilities and programs. Recent solicitations show demand for finished injectable formulations (vials, injections) with strict expiration-date requirements, compliance with cGMP and FDA standards, and delivery windows measured in days. Issuing bodies include city fire departments, state health agencies, and multi-state cooperative purchasing alliances. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent the types of state and local customers actively sourcing under related pharmaceutical codes, though the specific imidapril formulation shows limited recent direct solicitation activity.

Activity under the code spans multiple states, with recent opportunities posted in Florida, Texas, and Minnesota through cooperative purchasing arrangements. The City of Tampa issued an IFB (Bid No. 26P00188) due April 8, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem formulations for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus two optional one-year renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued an RFP (S1070000015802) closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson across participating state and local facilities in Minnesota, Oregon, and other alliance members, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on March 27, 2026, to explore direct-to-manufacturer prescription programs as a foundational market-intelligence phase prior to formal procurement. State and local pharmaceutical solicitations typically require vendors to demonstrate cGMP and DSCSA compliance, maintain relationships with authorized wholesalers, provide detailed NDC and product data, and carry comprehensive insurance; set-asides and preference programs vary by issuing body, with Tampa offering a 5 percent SLBE bid discount capped at $10,000.